link href="css/mac_print.css" rel="stylesheet" type"text/css" media="print">

Health Research Methods, Evidence, and Impact


Mark Levine

MD (McGill) MSc. (McMaster)

Professor, Department of Health Research Methods, Evidence, and Impact

Joint Member, Department of Oncology

Director, Clinical Trials Methodology Group

Medical Oncologist , Juravinski Cancer Clinic, Hamilton Health Sciences

Chairman, Health Canada Steering Committee on Clinical Practice Guidelines
for the Care and Treatment of Breast Cancer (for guidelines click here)

Associate Editor, Journal of Clinical Oncology

Member, Supportive Cancer Care Research Unit

905.527.4322 x42176
905.389.9288
mlevine@mcmaster.ca

Henderson Research Centre
711 Concession St.
Hamilton, Ontario, Canada
L8V 1C2

Office location: Henderson Research Centre, Rm 104

Administrative Assistant: Lori Dale
905.527.4322 x42176
905.389.9288
dalel@mcmaster.ca

Academic Interests

Dr. Levine is an active clinical trials investigator in the areas of breast cancer, venous thromboembolism, and has performed research in quality of life and decision-making in breast cancer. The Clinical Trials Methodology Group which he leads is conducting trials in a number of areas including: radiation therapy in breast and prostate cancers, vaccine therapy in breast cancer, and evaluation of PET imaging in oncology.

Selected Publications

  1. Kathleen I. Pritchard, M.D., Lois E. Shepherd, M.D., Frances P. O'Malley, M.D., Irene L. Andrulis, Ph.D., Dongsheng Tu, Ph.D., Vivien H. Bramwell, M.B., B.S., Mark N. Levine, M.D., for the National Cancer Institute of Canada Clinical Trials Group. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. New England Journal of Medicine 354:2103-2111, 2006.
  2. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AJ, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, and Gent M, for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT)Investigators. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine 349:146-153, 2003.
  3. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu­Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D for the National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. Journal of Clinical Oncology 16:2651-2658, 1998.
  4. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W and DePauw S. The thrombogenic effect of anti-cancer drug therapy in women with stage II breast cancer. New England Journal of Medicine 318:404-407, 1988.
  5. Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S and Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 334:677-681, 1996.
  6. Levine MN, Gafni A, Markham B and MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Annals of Internal Medicine 117:53-58, 1992.
    Search for citations for Dr. Mark Levine on PubMed

Search for citations for Dr. Mark Levine on PubMed